{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:24:49Z","timestamp":1768461889338,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We examined the correlation between the dosing regimen of oral prednisolone (PSL) and the achievement of minimal manifestation status or better on PSL \u22645\u2009mg\/day lasting &gt;6 months (the treatment target) in patients with generalised myasthenia gravis (MG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We classified 590 patients with generalised MG into high-dose (n=237), intermediate-dose (n=187) and low-dose (n=166) groups based on the oral PSL dosing regimen, and compared the clinical characteristics, previous treatments other than PSL and prognosis between three groups. The effect of oral PSL dosing regimen on the achievement of the treatment target was followed for 3 years of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>To achieve the treatment target, ORs for low-dose versus high-dose regimen were 10.4 (P&lt;0.0001) after 1\u2009year of treatment, 2.75 (P=0.007) after 2 years and 1.86 (P=0.15) after 3 years; and those for low-dose versus intermediate-dose regimen were 13.4 (P&lt;0.0001) after 1\u2009year, 3.99 (P=0.0003) after 2 years and 4.92 (P=0.0004) after 3 years. Early combined use of fast-acting treatment (OR: 2.19 after 2 years, P=0.02; OR: 2.11 after 3 years, P=0.04) or calcineurin inhibitors (OR: 2.09 after 2 years, P=0.03; OR: 2.36 after 3 years, P=0.02) was associated positively with achievement of treatment target.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A low-dose PSL regimen with early combination of other treatment options may ensure earlier achievement of the treatment target in generalised MG.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2017-316625","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T17:21:26Z","timestamp":1511544086000},"page":"513-517","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan"],"prefix":"10.1136","volume":"89","author":[{"given":"Tomihiro","family":"Imai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Nagane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Akaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"2020050722294633000_89.5.513.1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150316"},{"key":"2020050722294633000_89.5.513.2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"2020050722294633000_89.5.513.3","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.9.3.351"},{"key":"2020050722294633000_89.5.513.4","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107"},{"key":"2020050722294633000_89.5.513.5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"2020050722294633000_89.5.513.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"2020050722294633000_89.5.513.7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"2020050722294633000_89.5.513.8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clinical and Experimental Neuroimmunology"},{"key":"2020050722294633000_89.5.513.9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"2020050722294633000_89.5.513.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"2020050722294633000_89.5.513.11","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"2020050722294633000_89.5.513.12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mus.24438","article-title":"Oral corticosteroid therapy and present disease status in myasthenia gravis","volume":"51","author":"Imai","year":"2015","journal-title":"Muscle Nerve"},{"key":"2020050722294633000_89.5.513.13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clinph.2011.07.044","article-title":"Reference values for voluntary and stimulated single-fibre EMG using concentric needle electrodes: a multicentre prospective study","volume":"123","author":"Kokubun","year":"2012","journal-title":"Clin Neurophysiol"},{"key":"2020050722294633000_89.5.513.14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"2020050722294633000_89.5.513.15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000322497","article-title":"Early aggressive treatment strategy against myasthenia gravis","volume":"65","author":"Nagane","year":"2011","journal-title":"Eur Neurol"},{"key":"2020050722294633000_89.5.513.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.43.7.644"},{"key":"2020050722294633000_89.5.513.17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1212\/WNL.0000000000002796","article-title":"Treating myasthenia on consensus guide: helpful and challenging but still unfinished business","volume":"87","author":"Dalakas","year":"2016","journal-title":"Neurology"},{"key":"2020050722294633000_89.5.513.18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"2020050722294633000_89.5.513.19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300148"},{"key":"2020050722294633000_89.5.513.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"2020050722294633000_89.5.513.21","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45"},{"key":"2020050722294633000_89.5.513.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"2020050722294633000_89.5.513.23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cen3.12188","article-title":"Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: a retrospective analysis of outcomes","volume":"6","author":"Utsugisawa","year":"2015","journal-title":"Clinical and Experimental Neuroimmunology"},{"key":"2020050722294633000_89.5.513.24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"2020050722294633000_89.5.513.25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-316625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T19:54:17Z","timestamp":1603396457000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-316625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,24]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,12]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/jnnp-2017-316625"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-316625","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,24]]}}}